TreatIng Microalbuminuria Over 24 Weeks in Subjects With or Without Type 2 Diabetes or HYpertension

Inclusion Criteria:

• Age 45 to 80 years
• Persistent urinary albumin:creatinine ratio (UACR) ≥ 2.5 mg/mmol (~25 mg/g)
• Willing to sign informed consent

Exclusion Criteria: Diagnosis of type 1 diabetes mellitus

• eGFR < 25 ml/min/1.73m2
• UACR > 3500 mg/g
• Concurrent treatment with SGLT2 inhibitor
• Receiving immunosuppressive therapy within 6 months prior to enrolment
• History of diabetic ketoacidosis
• Active malignancy aside from treated squamous cell or basal cell carcinoma of theskin.
• Initiation or changes in the dose of interventions in therenin-angiotensinaldosterone- system, diuretics, GLP-1 receptor agonists within 6weeks of screening will not be allowed.
• Any medication, surgical or medical condition which might significantly alter theabsorption, distribution, metabolism, or excretion of medications including, but notlimited to any of the following:
• History of active inflammatory bowel disease within the last six months;
• Major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, orbowel resection;
• Gastro-intestinal ulcers and/or gastrointestinal or rectal bleeding within lastsix months;
• Pancreatic injury or pancreatitis within the last six months;
• Evidence of hepatic disease as determined by any one of the following: ALT or ASTvalues exceeding 3x ULN at the screening visit, a history of hepaticencephalopathy, a history of esophageal varices, or a history of portocavalshunt;
• Evidence of urinary obstruction or difficulty in voiding at screening
• History of severe hypersensitivity or contraindications to dapagliflozin
• Subjects who, in the assessment of the investigator, may be at risk for dehydration orvolume depletion that may affect the interpretation of efficacy or safety data
• Participation in any clinical intervention study within 3 months prior to initialdosing.
• History of drug or alcohol abuse within the 12 months prior to dosing, or evidence ofsuch abuse as indicated by the laboratory assays conducted during the screening.
• History of noncompliance to medical regimens or unwillingness to comply with the studyprotocol.
• Any surgical or medical condition, which in the opinion of the investigator, may placethe patient at higher risk from his/her participation in the study, or is likely toprevent the patient from complying with the requirements of the study or completingthe study.
• Pregnancy or breastfeeding